Baseline SUVmax May Have Prognostic Value in Patients With Follicular Lymphoma
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
Non-Hodgkin Lymphoma
Brentuximab Vedotin May Improve Outcomes in Anaplastic Large Cell Lymphoma
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
Loncastuximab Tesirine ‘Could Change Practice’ for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
Umbralisib Has Favorable Benefit-Risk Profile in Pretreated Patients With Indolent Non-Hodgkin Lymphoma
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
AlloHCT Following Treatment With PD-1 mAbs Beneficial in Classic Hodgkin Lymphoma
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
Biosimilar Riabni Gets FDA Approval
The biosimilar has been approved for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.
Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Intensive Chemotherapy Tolerable, Efficacious in HIV-Associated Burkitt Lymphoma
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL
The bispecific CAR-T therapy targets CD20 and CD19.
- Loading...
Loading...
Next post in ASH 2020
Loading... 
Loading...